Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Gland Pharma Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 785 | 1,209 | 1,373 | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 |
| Expenses + | 617 | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 |
| Operating Profit | 168 | 294 | 324 | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 |
| OPM % | 21% | 24% | 24% | 23% | 23% | 19% | 21% | 26% | 24% | 24% | 21% | 26% | 29% |
| Other Income + | -18 | 38 | 53 | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 39 | 111 |
| Interest | 2 | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 |
| Depreciation | 38 | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 |
| Profit before tax | 111 | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 |
| Tax % | 29% | 26% | 33% | 32% | 35% | 34% | 36% | 32% | 35% | 31% | 35% | 28% | 28% |
| Net Profit + | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 |
| EPS in Rs | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 |
Financials of Gland Pharma Ltd
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 2,633 | 3,463 | 4,401 | 3,625 | 5,665 | 5,616 | 6,431 |
| Expenses + | 1,678 | 2,161 | 2,890 | 2,600 | 4,332 | 4,348 | 4,801 |
| Operating Profit | 955 | 1,302 | 1,510 | 1,025 | 1,333 | 1,269 | 1,630 |
| OPM % | 36% | 38% | 34% | 28% | 24% | 23% | 25% |
| Other Income + | 139 | 135 | 224 | 184 | 170 | 214 | 292 |
| Interest | 7 | 3 | 5 | 7 | 26 | 42 | 33 |
| Depreciation | 95 | 99 | 110 | 147 | 345 | 378 | 424 |
| Profit before tax | 993 | 1,335 | 1,619 | 1,055 | 1,133 | 1,063 | 1,465 |
| Tax % | 22% | 25% | 25% | 26% | 32% | 34% | 30% |
| Net Profit + | 773 | 997 | 1,212 | 781 | 772 | 699 | 1,027 |
| EPS in Rs | 49.88 | 60.94 | 73.75 | 47.42 | 46.90 | 42.40 | 62.35 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 43% | 42% | 32% |
Financials of Gland Pharma Ltd
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 | 10,341 |
| Borrowings + | 5 | 4 | 5 | 4 | 372 | 314 | 284 |
| Other Liabilities + | 435 | 589 | 671 | 814 | 1,515 | 1,708 | 1,869 |
| Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 | 12,511 |
| Fixed Assets + | 968 | 954 | 1,502 | 1,571 | 3,947 | 4,147 | 4,492 |
| CWIP | 188 | 338 | 191 | 177 | 238 | 151 | 342 |
| Investments | 0 | 0 | 155 | 0 | 0 | 0 | 0 |
| Other Assets + | 2,929 | 5,204 | 5,986 | 7,030 | 6,426 | 6,875 | 7,676 |
| Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 | 12,511 |
Financials of Gland Pharma Ltd
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 701 | 605 | 791 | 364 | 997 | 915 | 1,031 |
| Cash from Investing Activity + | -761 | -1,520 | -999 | 1,211 | -1,749 | 1,718 | 138 |
| Cash from Financing Activity + | -7 | 1,238 | 35 | 15 | -799 | -433 | -417 |
| Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 | 2,199 | 752 |
| Free Cash Flow | 530 | 377 | 269 | 141 | 599 | 521 | 538 |
| CFO/OP | 99% | 70% | 79% | 66% | 98% | 100% | 91% |
Financials of Gland Pharma Ltd
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 71 | 89 | 88 | 100 | 99 | 107 |
| Inventory Days | 250 | 312 | 205 | 421 | 278 | 294 | 284 |
| Days Payable | 82 | 98 | 80 | 127 | 129 | 143 | 136 |
| Cash Conversion Cycle | 251 | 285 | 214 | 382 | 250 | 250 | 255 |
| Working Capital Days | 161 | 169 | 168 | 242 | 155 | 173 | 145 |
| ROCE % | 28% | 25% | 15% | 14% | 12% | 15% |